Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
The American Journal of Gastroenterology
|
November 2, 2017
Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Philip Schoenfeld, Brian E Lacy, William D Chey, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
December 17, 2020
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial
John P Hanrahan, Ian H de Boer, George L Bakris, et al.
The American Journal of Gastroenterology
|
September 19, 2012
A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation
Satish Rao, Anthony J Lembo, Steven J Shiff, et al.
The New England Journal of Medicine
|
August 12, 2011
Two randomized trials of linaclotide for chronic constipation
Anthony J Lembo, Harvey A Schneier, Steven J Shiff, et al.
Journal of Neuroinflammation
|
September 19, 2021
The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system
Susana S Correia, Guang Liu, Sarah Jacobson, et al.
Diabetologia
|
December 21, 2019
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension
John P Hanrahan, Jelena P Seferovic, James D Wakefield, et al.
Pain
|
June 11, 2013
Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation
Inmaculada Silos-Santiago, Gerhard Hannig, Helene Eutamene, et al.
ACS Medicinal Chemistry Letters
|
May 19, 2016
Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans
Takashi Nakai, Nicholas R Perl, Timothy C Barden, et al.
Gastroenterology
|
August 21, 2013
Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate
Joel Castro, Andrea M Harrington, Patrick A Hughes, et al.
Frontiers in Pharmacology
|
June 10, 2021
The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases
Susana S Correia, Rajesh R Iyengar, Peter Germano, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
The American Journal of Gastroenterology
|
November 2, 2017
Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Philip Schoenfeld, Brian E Lacy, William D Chey, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
December 17, 2020
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial
John P Hanrahan, Ian H de Boer, George L Bakris, et al.
The American Journal of Gastroenterology
|
September 19, 2012
A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation
Satish Rao, Anthony J Lembo, Steven J Shiff, et al.
The New England Journal of Medicine
|
August 12, 2011
Two randomized trials of linaclotide for chronic constipation
Anthony J Lembo, Harvey A Schneier, Steven J Shiff, et al.
Journal of Neuroinflammation
|
September 19, 2021
The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system
Susana S Correia, Guang Liu, Sarah Jacobson, et al.
Diabetologia
|
December 21, 2019
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension
John P Hanrahan, Jelena P Seferovic, James D Wakefield, et al.
Pain
|
June 11, 2013
Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation
Inmaculada Silos-Santiago, Gerhard Hannig, Helene Eutamene, et al.
ACS Medicinal Chemistry Letters
|
May 19, 2016
Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans
Takashi Nakai, Nicholas R Perl, Timothy C Barden, et al.
Gastroenterology
|
August 21, 2013
Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate
Joel Castro, Andrea M Harrington, Patrick A Hughes, et al.
Frontiers in Pharmacology
|
June 10, 2021
The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases
Susana S Correia, Rajesh R Iyengar, Peter Germano, et al.
Page
of 5